| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2023-054 | | --- | --- | --- | | 债券代码：111015 | 转债简称：东亚转债 | | 浙江东亚药业股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示：拟回购股份的用途：拟用于实施浙江东亚药业股份有限 公司（以下简称"公司"）员工持股计划或股权激励。 拟回购股份资金总额：不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含）。 回购期限：自董事会审议通过本回购股份方案之日起不超过 12 个月。 回购价格：不超过人民币 39.18 元/股（含），该回购价格不超过董事会 通过回购股份决议前 30 个交易日公司股票交易均价的 150%。 回购资金来源：公司自有资金。 相关股东是否存在减持计划：经向公司董监高、控股股东、实际控制人、 持股 5%以上的股东发出问询函，问询在未来 3 个月、未来 6 个月是否存 在减持计划。截至第三届董事会第十七次会议 ...

浙江东亚药业股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江东亚药业股份有限公司（以下简称"公司"、"东亚药业"）近日收到 东兴证券股份有限公司（以下简称"东兴证券"）《关于更换浙江东亚药业股份 有限公司持续督导保荐代表人的函》。 东兴证券作为公司首次公开发行股票并上市的保荐机构，原指定阮瀛波先生、 张昱先生作为公司首次公开发行股票并上市项目保荐代表人，负责保荐工作及持 续督导工作，持续督导期至 2022 年 12 月 31 日。截至目前，公司首次公开发行 股票并上市的募集资金尚未使用完毕，根据相关规定，东兴证券对此未尽事项继 续履行持续督导义务。 | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2023-052 | | --- | --- | --- | | 债券代码：111015 | 转债简称：东亚转债 | | 特此公告。 1 浙江东亚药业股份有限公司 董事会 2023 年 8 月 8 日 附件： 曾文倩女士简历 曾文倩女士，保荐代表人，经济学硕士，东兴 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2023-053 | | --- | --- | --- | | 债券代码：111015 | 转债简称：东亚转债 | | 浙江东亚药业股份有限公司 关于回购股份事项前十大股东和前十大无限售条件股东 持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2023 年 8 月 1 日，浙江东亚药业股份有限公司（以下简称"公司"）召开第三 届董事会第十七次会议，审议通过了《关于以集中竞价交易方式回购公司股份方 案的议案》，具体内容详见公司于 2023 年 8 月 2 日在上海证券交易所网站 （www.sse.com.cn）披露的《东亚药业关于以集中竞价交易方式回购公司股份方 案的公告》（公告编号：2023-051）。 浙江东亚药业股份有限公司 1 序号 股东名称 持股数量（股） 占公司总股本 的比例（%） 1 池正明 47,116,769 41.48 2 池骋 7,786,875 6.85 3 台州市瑞康投资合伙企业（有限合伙） 2,500,000 2.20 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥369,701,875.56, representing a 45.00% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥23,220,016.44, reflecting a 3.38% increase year-over-year[5] - The basic earnings per share remained at ¥0.20, unchanged from the previous year[6] - Total operating revenue for Q1 2023 reached RMB 369,701,875.56, a significant increase of 45% compared to RMB 254,966,058.04 in Q1 2022[19] - The net profit attributable to shareholders for Q1 2023 was CNY 23,220,016.44, compared to CNY 22,461,105.10 in Q1 2022, reflecting an increase of about 3.4%[21] - The company reported a total profit of CNY 26,360,261.89 for Q1 2023, slightly up from CNY 25,854,576.56 in Q1 2022, an increase of about 2.0%[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,510,323,347.67, an increase of 1.58% from the end of the previous year[6] - Total assets as of March 31, 2023, were RMB 2,510,323,347.67, compared to RMB 2,471,356,543.29 at the end of 2022, marking an increase of about 1.6%[17] - Total liabilities increased to RMB 647,314,075.24 from RMB 631,567,287.30, reflecting an increase of approximately 2.8%[17] - Non-current liabilities rose to RMB 84,864,150.76 from RMB 61,876,760.07, representing an increase of about 37%[17] Cash Flow and Working Capital - The net cash flow from operating activities was negative at -¥76,560,280.97, indicating a significant cash outflow[5] - The net cash flow from operating activities for Q1 2023 was negative CNY 76,560,280.97, worsening from negative CNY 14,747,411.47 in Q1 2022[24] - Cash and cash equivalents as of March 31, 2023, amounted to RMB 437,615,919.58, down from RMB 501,581,622.26 at the end of 2022, representing a decrease of approximately 12.7%[15] - Cash and cash equivalents at the end of Q1 2023 stood at CNY 437,615,919.58, down from CNY 497,876,603.38 at the end of Q1 2022, a decrease of about 12.1%[25] - Accounts receivable increased to RMB 185,439,119.64 from RMB 98,453,246.26, reflecting an increase of about 88.3% year-over-year[15] - Inventory decreased to RMB 458,031,512.77 from RMB 482,836,761.74, indicating a reduction of approximately 5.1%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,071[10] - The largest shareholder, Chi Zhengming, holds 41.48% of the shares, totaling 47,116,769 shares[11] - The company’s actual controllers are Chi Zhengming and Chi Cheng, holding a combined 48.33% of the shares[12] Operational Highlights - The increase in revenue was primarily driven by the new production line for cefazolin sodium intermediates, which significantly boosted production and sales compared to last year[9] - The company has not reported any significant new product developments or market expansions during this quarter[13] - The total operating costs for Q1 2023 were CNY 337,139,935.76, an increase from CNY 228,080,537.00 in Q1 2022, representing a growth of approximately 47.9%[20] - Research and development expenses rose to CNY 14,248,858.89 in Q1 2023, up from CNY 8,485,988.91 in Q1 2022, marking a significant increase of approximately 67.5%[20] Non-Recurring Items - Non-recurring gains and losses included a government subsidy of ¥1,462,109.01, contributing positively to the financial results[8] - The company incurred a credit impairment loss of CNY -5,577,518.48 in Q1 2023, compared to CNY -2,159,337.30 in Q1 2022, indicating a deterioration in credit quality[20]

Financial Performance - The company's operating revenue for 2022 was CNY 1,179,556,669.18, representing a year-on-year increase of 65.62%[23]. - The net profit attributable to shareholders for 2022 was CNY 104,423,862.82, an increase of 52.46% compared to the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 96.55% to CNY 93,749,071.41 in 2022[23]. - The basic earnings per share for 2022 rose by 53.33% to CNY 0.92[24]. - The weighted average return on equity increased to 5.80%, up by 1.86 percentage points from the previous year[25]. - The total assets at the end of 2022 were CNY 2,471,356,543.29, a 9.79% increase from the end of 2021[23]. - The company's equity attributable to shareholders increased by 4.65% to CNY 1,839.79 million compared to the previous year[35]. - The company's total revenue for 2022 was 406,318.19 million CNY, with a gross margin of 35.23%[104]. Cash Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 2.9 per 10 shares, totaling RMB 32,944,000, subject to shareholder approval[5]. - The company will carry forward the remaining undistributed profits to future years[5]. - The company has no plans for stock dividends or capital reserve transfers in the current profit distribution proposal[5]. - The company's cash dividend distribution is based on achieving positive distributable profits and receiving an unqualified audit report[176]. - The company has a history of cash dividend distribution, with a cash dividend of 3.5 RMB per 10 shares distributed in 2021, totaling 39,760,000 RMB, which accounted for 34.73% of the net profit for 2020[184]. Audit and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[4]. - The financial report is guaranteed to be true, accurate, and complete by the board of directors and senior management[8]. - The company has established a strict internal control management system to enhance decision-making efficiency and ensure compliance and asset safety[191]. - The company received a standard unqualified opinion in the internal control audit report for 2022[192]. - The company has no significant deficiencies in internal control over subsidiaries during the reporting period[191]. Operational Risks and Challenges - There are no significant risks that materially affect the company's operations during the reporting period[8]. - The company faces risks from increasing competition in the raw materials and pharmaceutical intermediates market[135]. - The company is adapting to stricter regulatory requirements in the pharmaceutical industry, which may impact its operations[135]. - Environmental regulations are becoming stricter, increasing the pressure on the company to comply, which may lead to higher costs and impact profitability[140]. Research and Development - The company has over 30 invention patents and has been recognized as a national high-tech enterprise, indicating strong R&D capabilities[55]. - Research and development expenses increased by 20.53% to ¥44,947,984.62, indicating a continued investment in innovation[61]. - The company is focused on expanding its market presence through strategic partnerships and collaborations with downstream clients for product development[47]. - The company is investing in research and development to enhance its antibiotic portfolio, ensuring a strong market presence in the face of increasing competition[99]. Market Strategy and Expansion - The company plans to expand its production capacity for β-lactam antibiotics, which has been a significant driver of revenue growth[26]. - The company is focusing on expanding its market presence through strategic partnerships and potential acquisitions to enhance its competitive edge in the pharmaceutical industry[102]. - The company is committed to integrating high-end raw materials and formulations, aiming for a collaborative development of these products[131]. - The company is exploring potential mergers and acquisitions to strengthen its position in the pharmaceutical market[98]. Corporate Governance - The company has established a robust investor relations management system to maintain effective communication with investors and keep them informed about the company's operational developments[146]. - The company emphasizes respect for stakeholders, including customers, employees, suppliers, and the public, to promote sustainable development and enhance both economic and social benefits[146]. - The company has established a sound corporate governance structure, ensuring compliance with relevant laws and protecting shareholder rights[144]. - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making and operations[145]. Environmental and Social Responsibility - The company invested 75.08 million yuan in environmental protection during the reporting period[194]. - The total non-methane hydrocarbon emissions for the year 2022 were 1.1012 tons, with an average emission concentration of 13.66 mg/m³[195]. - The total wastewater discharge for the year 2022 was 52,971.7436 tons, with a chemical oxygen demand average emission concentration of 209.95 mg/L[196]. - The company has no instances of exceeding pollutant discharge standards during the reporting period[196].

证券代码：605177 证券简称：东亚药业 公告编号：2023-026 浙江东亚药业股份有限公司 关于举办2022年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会 议 问 题 征 集 ： 投 资 者 可 于 2023 年 5 月 5 日 前 访 问 网 址 https://eseb.cn/12mYieqi3BK 或使用微信扫描下方小程序码进行会前提问，公司将 通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回答。 一、说明会类型 浙江东亚药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 11 日在 上海证券交易所网站（www.sse.com.cn）披露了《2022 年年度报告》及《2022 年 年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战 略等情况，公司定于 2023 年 5 月 5 日（星期五）10:00-11:00 在"价值在线" （www.ir-online.cn）举办东亚药业（605177）2022 年度业绩说明会，与投资 ...

2022 年第三季度报告 证券代码：605177 证券简称：东亚药业 浙江东亚药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 年同期增减变 | 年初至报告期 | 年初至报告 期末比上年 | | --- | --- | --- | --- | --- | | | | 动幅度(%) | 末 | 同期增减变 | | | | | | 动幅度(%) | | 营业收入 | 319,176,998.90 | 150.64 | 854,512,627.54 | 80.89 | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥535,335,628.64, representing a 55.14% increase compared to ¥345,057,772.80 in the same period last year[21]. - The net profit attributable to shareholders decreased by 27.78% to ¥41,975,406.67 from ¥58,117,927.24 year-on-year[21]. - The net cash flow from operating activities turned negative at -¥57,135,955.61, a decrease of 210.27% compared to ¥51,813,693.39 in the previous year[21]. - The basic earnings per share for the first half of 2022 was ¥0.37, down 27.45% from ¥0.51 in the same period last year[22]. - The company's total assets at the end of the reporting period were ¥2,256,590,473.70, a slight increase of 0.24% from ¥2,251,076,133.47 at the end of the previous year[21]. - The company's net assets attributable to shareholders increased by 1.10% to ¥1,777,340,799.84 from ¥1,758,085,393.17 at the end of the previous year[21]. - The company reported a decrease in the weighted average return on net assets to 2.37%, down from 3.32% in the previous year, a reduction of 0.95 percentage points[22]. - The company reported non-recurring gains of ¥6,022,716.07 for the period, after accounting for tax effects[24]. Operational Insights - The company is engaged in the research, production, and sales of chemical raw materials and pharmaceutical intermediates, focusing on various medication fields including antibacterial drugs and antifungal medications[27]. - The sales volume of β-lactam raw materials and intermediates contributed significantly to the revenue increase during the reporting period[22]. - The procurement department ensures the supply of raw materials and packaging materials, selecting at least two qualified suppliers for major raw materials to avoid inventory buildup[30]. - The production process involves multiple steps, with intermediates being produced for both internal use and external sales, ensuring compliance with quality management standards[31]. - The sales model primarily focuses on direct sales in the domestic market, while the international market utilizes both direct and distributor sales strategies[32]. - The company collaborates with downstream clients' R&D institutions for early product development, facilitating sales once products enter mass production[33]. - The company maintains a strong relationship with distributors to enhance market reach and efficiency in international sales[33]. Market and Industry Trends - The chemical pharmaceutical industry is experiencing rapid growth due to increasing healthcare demands driven by economic growth and an aging population[37]. - The "14th Five-Year" plan for bio-economy aims to enhance the development of biopharmaceuticals and related industries, emphasizing innovation and integration across sectors[38]. - By 2025, the bio-economy is expected to become a strong driver of high-quality development, with significant improvements in technological capabilities and industry integration[41]. - The company is positioned to benefit from the government's focus on biopharmaceuticals, with a target industry output value of 450 billion yuan by 2024 in Zhejiang province alone[43]. Environmental Compliance - The company reported a total non-methane hydrocarbon emission of 0.46 tons for the first half of 2022, with an average emission concentration of 15.36 mg/m3[86]. - The total wastewater discharge for the first half of 2022 was 30,675.8 tons, with a chemical oxygen demand average concentration of 215.11 mg/L[87]. - The company achieved a total SO2 emission of 0.223245 tons and NOx emission of 0.287533 tons in the first half of 2022[88]. - The company has no instances of exceeding pollutant discharge standards in the first half of 2022[87]. - The company is committed to environmental standards, adhering to the chemical synthesis pharmaceutical industry air pollutant discharge standards[86]. - The company has established an environmental self-monitoring plan, with third-party monitoring showing that all pollutant indicators meet discharge standards[98]. - The company has received ISO 14001 certification for its environmental management system[99]. Corporate Governance and Shareholder Relations - The company approved the financial budget report for 2022 during the annual general meeting held on April 21, 2022[80]. - The company plans to issue convertible bonds and has approved the feasibility analysis report for the use of raised funds[82]. - The controlling shareholder is required to propose a share buyback plan within ten trading days after triggering stock price stabilization measures, with a minimum buyback amount not less than 10% of the last cash dividend received[111]. - If the stock price remains below the latest audited net asset value for five consecutive trading days, the board must initiate a share repurchase plan within ten trading days[112]. - The company will communicate with shareholders, especially small and medium shareholders, through various channels to gather opinions and address concerns[112]. - The company has established a comprehensive profit distribution system and plans to further improve its profit distribution mechanism to enhance investor returns[111]. Financial Management and Investments - The company has invested a total of CNY 1,660,473,050.00 in various projects, with CNY 132,350,516.35 remaining at the end of the reporting period[63]. - The company plans to raise up to CNY 700 million through convertible bonds to invest in new drug formulation and production facilities[53]. - The company is focusing on expanding its production capabilities and enhancing its R&D center, with significant investments planned for the future[63]. - The implementation of fundraising investment projects is crucial for expanding product variety and capacity, but may face risks related to project delays and market development[76]. Risks and Challenges - The company is exposed to risks from regulatory changes in the pharmaceutical industry, which could increase operational costs and affect business models[74]. - Environmental regulations are becoming stricter, potentially increasing compliance costs and impacting profitability[77]. - Quality control is critical, as any issues in the production process could lead to product recalls and legal disputes, affecting market reputation[78]. - The company is located in a region prone to natural disasters, which poses additional operational risks[79].

Financial Performance - The company's operating revenue for Q1 2022 was ¥254,966,058.04, representing a year-on-year increase of 34.45%[5] - The net profit attributable to shareholders decreased by 8.47% to ¥22,461,105.10 compared to the same period last year[5] - Basic earnings per share (EPS) was ¥0.20, down by 9.09% from the previous year[5] - The net profit for Q1 2022 was 22,461,105.10, a decrease of 8.5% compared to 24,540,005.70 in Q1 2021[23] - Operating profit for Q1 2022 was 28,111,108.02, down from 30,644,882.75 in the same period last year, reflecting a decline of 8.3%[26] - Total revenue from sales of goods and services in Q1 2022 was 164,651,123.39, an increase of 19.9% from 137,367,582.36 in Q1 2021[26] - The company reported a total comprehensive income of 22,461,105.10 for Q1 2022, which is a decrease of 8.5% from 24,540,005.70 in Q1 2021[23] - Basic and diluted earnings per share for Q1 2022 were both 0.20, down from 0.22 in Q1 2021[23] Cash Flow and Assets - The net cash flow from operating activities was negative at ¥-14,747,411.47, a decline of 131.47% year-on-year[5][10] - Cash and cash equivalents as of March 31, 2022, were RMB 497,876,603.38, down from RMB 556,101,874.98 at the end of 2021, representing a decrease of 10.4%[17] - The cash flow from operating activities in Q1 2022 was negative at -14,747,411.47, compared to a positive cash flow of 46,869,087.68 in Q1 2021[26] - The cash and cash equivalents at the end of Q1 2022 were 497,876,603.38, down from 682,797,022.76 at the end of Q1 2021[27] - The total cash outflow from investing activities in Q1 2022 was -35,703,896.75, compared to -288,867,107.27 in Q1 2021, indicating a significant reduction in cash outflow[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,271,868,148.48, an increase of 0.92% from the end of the previous year[6] - Total assets as of March 31, 2022, amounted to RMB 2,271,868,148.48, compared to RMB 2,251,076,133.47 at the end of 2021, indicating a growth of 0.9%[19] - Total liabilities as of March 31, 2022, were RMB 491,321,650.21, slightly down from RMB 492,990,740.30 at the end of 2021[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,023[12] - The largest shareholder, Chi Zhengming, holds 41.48% of the shares, totaling 47,116,769 shares[13] Operating Costs and Expenses - Total operating costs for Q1 2022 were RMB 228,080,537.00, up 41.5% from RMB 160,904,935.12 in Q1 2021[21] - Research and development expenses for Q1 2022 were 8,485,988.91, a decrease of 15.1% compared to 9,997,252.39 in Q1 2021[26] - The company incurred a financial expense of -3,544,370.85 in Q1 2022, an improvement from -6,212,055.12 in Q1 2021[26] Other Information - The company experienced a significant increase in sales revenue, which was the primary reason for the growth in operating income[10] - The company has not disclosed any new product developments or market expansion strategies in the provided documents[15] - There are no significant mergers or acquisitions reported during the quarter[15]

Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.0 per 10 shares, totaling RMB 22,720,000.00, subject to shareholder approval[5]. - The company has no plans for stock dividends or capital reserve transfers in the current profit distribution proposal[5]. - The proposed cash dividend for 2021 is RMB 2.0 per 10 shares, expected to total RMB 22,720,000, representing 33.17% of the net profit attributable to shareholders[197]. - In 2020, the company distributed a cash dividend of RMB 3.5 per 10 shares, totaling RMB 39,760,000, which accounted for 34.73% of the net profit attributable to shareholders[197]. - The cash dividend policy requires at least 20% of the distributable profits to be distributed in cash if the company is profitable and meets the conditions for cash dividends[195]. - The company's cash dividend conditions require that the distributable profits must be positive and that the financial report receives an unqualified audit opinion[191]. Financial Performance - In 2021, the company's operating revenue was CNY 712.22 million, a decrease of 19.22% compared to CNY 881.67 million in 2020[22]. - The net profit attributable to shareholders was CNY 68.49 million, down 40.17% from CNY 114.48 million in the previous year[22]. - The net cash flow from operating activities decreased by 116.06%, resulting in a negative cash flow of CNY 23.60 million[24]. - Basic earnings per share fell to CNY 0.60, a decline of 54.20% from CNY 1.31 in 2020[23]. - The total assets increased by 8.15% to CNY 2.25 billion, compared to CNY 2.08 billion in 2020[22]. - The company reported a significant drop in net profit due to factors such as safety and environmental upgrades, production line shutdowns, and the impact of the COVID-19 pandemic[23]. - The weighted average return on equity decreased to 3.94%, down 7.98 percentage points from 11.92% in 2020[23]. - The net profit after deducting non-recurring gains and losses was CNY 47.70 million, a decrease of 53.88% from CNY 103.42 million in 2020[22]. Operational Challenges - The company faced challenges such as raw material supply shortages and rising prices due to the ongoing pandemic, impacting production and sales[33]. - The company experienced a decline in inventory turnover, leading to increased cash outflows for inventory purchases[24]. - The company reported a loss of CNY 4.05 million from the disposal of non-current assets in 2021, compared to a loss of CNY 2.45 million in 2020[28]. - The pharmaceutical manufacturing industry is experiencing intensified competition and a reshuffling due to the pandemic and policy changes[39]. - The company is focusing on enhancing internal control management and governance levels in response to the challenges faced during the year[33]. Research and Development - The company emphasizes the importance of research and development in creating new products and improving existing ones, which is critical for maintaining competitive advantage[45]. - The company has over 30 invention patents and has been recognized as a national high-tech enterprise, indicating strong R&D capabilities[54]. - Research and development expenses amounted to CNY 37,290,482.52, reflecting a decrease of 2.92% compared to the previous year[78]. - The company has completed the research and development of multiple antibacterial drugs, including DB201904, DB202002, and DB202004, all classified as chemical drugs in category 4[101]. - The company has a total of 11 major research projects in various stages, including completed formulations and small-scale studies[101]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights and interests[144]. - The company has implemented a comprehensive insider information management system to prevent insider trading and protect minority shareholders' rights[152]. - The board of directors and supervisory board operate independently, with a focus on compliance and oversight of company operations[149]. - The company has not reported any significant differences in governance practices compared to regulatory requirements[153]. - The company has established a robust investor relations management system to maintain effective communication with investors[152]. Market Strategy - The company is focusing on enhancing product pipeline construction and optimizing production efficiency to reduce costs and improve product quality[91]. - The company aims to enhance production efficiency through the continuous improvement of production processes and adherence to industry regulations[45]. - The company is actively participating in the national drug procurement process, which is becoming a normalized and institutionalized practice[90]. - Future outlook includes plans to expand into international markets, targeting a 30% increase in overseas sales by 2023[96]. - The company plans to enhance its digital marketing efforts, with a projected increase in online sales by 50% in the upcoming year[96]. Risk Management - The company faces risks from increased competition in the raw materials and intermediates sector, particularly from emerging competitors in China and India[135]. - Regulatory changes in the pharmaceutical industry may impact operational costs and business models, posing a risk to the company's performance[136]. - The company is at risk of losing essential operating qualifications if it fails to renew necessary licenses and permits on time[137]. - Environmental regulations are tightening, which may increase compliance costs and impact profitability due to stricter standards[139]. - The company emphasizes safety production and has established multiple regulations, including a safety production responsibility system and fire management system, to mitigate risks associated with flammable and toxic materials[140].